癌症患者Aurora B表达的预后价值:一个元分析
Md Mojahidur Hasan1,2, Sehreen Tory1,2, Yusuf Kemal Arslan3
1Division of Biochemistry, Department of Basic Medical Sciences, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Türkiye.
Tumori
|May 30, 2025
概括
增加Aurora B蛋白表达不是癌症患者整体存活率 (OS) 差的可靠预测指标. 这次元分析在多项研究中发现,Aurora B水平和患者的结果之间没有显著的联系.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 极光B激酶与细胞分裂有关,并且在各种癌症中观察到其过度表达.
- 在恶性瘤中,Aurora B的预后价值受到争议,需要进一步调查.
研究的目的:
- 进行元分析,最终评估Aurora B蛋白表达在癌症患者中的预后意义.
- 为了确定升高的Aurora B水平是否与整体存活率 (OS) 差相关.
主要方法:
- 在多个数据库中进行了全面的文献搜索.
- 为了评估预后意义,计算了具有95%置信区间 (CI) 的聚合危险比率 (HR).
- 使用元回归和子组分析来确定异质性的来源.
主要成果:
- 分析包括了来自10项研究的数据,其中包括1384名癌症患者.
- 无论是多变量 (汇总HR=1.18,95%CI=0.71-1.95) 还是单变量 (汇总HR=1.81,95%CI=0.92-3.57) 的分析都显示,Aurora B表达和OS差之间没有显著的关联.
- 亚组分析显示,生存系统与样本大小,随访持续时间,切断值,患者种族或抗体来源等因素之间没有联系.
结论:
- 极光B蛋白表达不是癌症整体存活时间的可靠预后标志物.
- 目前的证据不支持使用Aurora B作为癌症患者管理中的预测生物标志物.
相关概念视频
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K